Log In
Print
BCIQ
Print
Print this Print this
 

Q-4

  Manage Alerts
Collapse Summary General Information
Company Qurient Co. Ltd.
DescriptionAXL inhibitor
Molecular Target AXL receptor tyrosine kinase (AXL) (UFO)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today